Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/1980
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGonzalez-Aparicio, Ramiro-
dc.contributor.authorBlanco, Eduardo-
dc.contributor.authorSerrano, Antonia-
dc.contributor.authorPavon, Francisco Javier-
dc.contributor.authorParsons, Loren H-
dc.contributor.authorMaldonado, Rafael-
dc.contributor.authorRobledo, Patricia-
dc.contributor.authorFernandez-Espejo, Emilio-
dc.contributor.authorRodríguez de Fonseca, Fernando-
dc.date.accessioned2015-09-10T10:45:35Z-
dc.date.available2015-09-10T10:45:35Z-
dc.date.issued2014-03-
dc.identifier.citationGonzalez-Aparicio R, Blanco E, Serrano A, Pavon FJ, Parsons LH, Maldonado R, et al. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. Int. J. Neuropsychopharmacol. 2014; 17(3):455-68es
dc.identifier.issn1469-5111 (Online)-
dc.identifier.issn1461-1457 (Print)-
dc.identifier.urihttp://hdl.handle.net/10668/1980-
dc.descriptionJournal Article; Research Support, Non-U.S. Gov't;es
dc.description.abstractOleoylethanolamide (OEA) is an agonist of the peroxisome proliferator-activated receptor α (PPARα) and has been described to exhibit neuroprotective properties when administered locally in animal models of several neurological disorder models, including stroke and Parkinson's disease. However, there is little information regarding the effectiveness of systemic administration of OEA on Parkinson's disease. In the present study, OEA-mediated neuroprotection has been tested on in vivo and in vitro models of 6-hydroxydopamine (6-OH-DA)-induced degeneration. The in vivo model was based on the intrastriatal infusion of the neurotoxin 6-OH-DA, which generates Parkinsonian symptoms. Rats were treated 2 h before and after the 6-OH-DA treatment with systemic OEA (0.5, 1, and 5 mg/kg). The Parkinsonian symptoms were evaluated at 1 and 4 wk after the development of lesions. The functional status of the nigrostriatal system was studied through tyrosine-hydroxylase (TH) and hemeoxygenase-1 (HO-1, oxidation marker) immunostaining as well as by monitoring the synaptophysin content. In vitro cell cultures were also treated with OEA and 6-OH-DA. As expected, our results revealed 6-OH-DA induced neurotoxicity and behavioural deficits; however, these alterations were less severe in the animals treated with the highest dose of OEA (5 mg/kg). 6-OH-DA administration significantly reduced the striatal TH-immunoreactivity (ir) density, synaptophysin expression, and the number of nigral TH-ir neurons. Moreover, 6-OH-DA enhanced striatal HO-1 content, which was blocked by OEA (5 mg/kg). In vitro, 0.5 and 1 μM of OEA exerted significant neuroprotection on cultured nigral neurons. These effects were abolished after blocking PPARα with the selective antagonist GW6471. In conclusion, systemic OEA protects the nigrostriatal circuit from 6-OH-DA-induced neurotoxicity through a PPARα-dependent mechanism.es
dc.description.sponsorshipThis work was supported by grants to EFE, RM and FRF from Fundació La Marató TV3, and Red de Trastornos Adictivos (Instituto de Salud Carlos III, RD06/0001/0002, RD06/0001/0001, RD06/0001/0005, and FEDER funds) and to EFE from Delegación del Gobierno para el Plan Nacional sobre Drogas (PNSD2009I039) and Junta de Andalucía (BIO127, PAIDI). EB is a recipient of a ‘Marie Curie’ COFUND Fellowship (U-Mobility, number 246550) from the University of Málaga and the 7th Framework Program (FP7)es
dc.language.isoenes
dc.publisherOxford University Presses
dc.relation.ispartofThe International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)es
dc.subjectDopaminergic neuronses
dc.subjectNeuroprotectiones
dc.subjectParkinson's diseasees
dc.subjectPPARxes
dc.subjectModelos de enfermedad en animaleses
dc.subjectRelación dosis-respuesta de medicamentoses
dc.subjectActividad motoraes
dc.subjectNeurotoxinases
dc.subjectÁcidos oleicoses
dc.subjectTrastornos parkinsonianoses
dc.subjectSustancia negraes
dc.subjectSinaptofisinaes
dc.subject.meshMedical Subject Headings::Anatomy::Cells::Cells, Culturedes
dc.subject.meshMedical Subject Headings::Anatomy::Nervous System::Central Nervous System::Brain::Prosencephalon::Telencephalon::Cerebrum::Basal Ganglia::Corpus Striatumes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Animal::Disease Models, Animales
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Druges
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Oxygenases::Mixed Function Oxygenases::Heme Oxygenase (Decyclizing)::Heme Oxygenase-1es
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Alcohol Oxidoreductases::Lactate Dehydrogenases::L-Lactate Dehydrogenasees
dc.subject.meshMedical Subject Headings::Check Tags::Malees
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activityes
dc.subject.meshMedical Subject Headings::Anatomy::Nervous System::Neuronses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Protective Agents::Neuroprotective Agentses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Toxic Actions::Noxae::Neurotoxinses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids, Unsaturated::Fatty Acids, Monounsaturated::Oleic Acidses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amines::Catecholamines::Dopamine::Hydroxydopamines::Oxidopaminees
dc.subject.meshMedical Subject Headings::Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorderses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Ratses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Rats::Rats, Wistares
dc.subject.meshMedical Subject Headings::Anatomy::Nervous System::Central Nervous System::Brain::Mesencephalon::Tegmentum Mesencephali::Substantia Nigraes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Synaptophysines
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Oxygenases::Mixed Function Oxygenases::Tyrosine 3-Monooxygenasees
dc.subject.meshMedical Subject Headings::Organisms::Eukaryotaes
dc.titleThe systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism.es
dc.typeinfo:eu-repo/semantics/articlees
dc.description.versionYeses
dc.identifier.pmid24169105-
dc.rights.accessRightsAcceso abiertoes
dc.identifier.doi10.1017/S1461145713001259-
dc.type.versioninfo:eu-repo/semantics/publishedes
dc.relation.publisherversionhttp://ijnp.oxfordjournals.org/content/17/3/455.longes
dc.contributor.authoraffiliation[Gonzalez-Aparicio,R; Fernandez-Espejo,E; Rodríguez de Fonseca,F] Instituto Cajal (CSIC), Madrid, Spain. [Gonzalez-Aparicio,R] Laboratorio de Neurología Molecular y Neurofisiología, Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain. [Blanco,E; Serrano,A; Pavon,FJ; Rodríguez de Fonseca,F] Laboratorio de Medicina Regenerativa, IBIMA, Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario Carlos Haya, Málaga, Spain. [Blanco,E]] Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Universidad de Málaga, Málaga, Spain. [Serrano,A; Pavon,FJ; Parsons,LH] Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, California, USA. Maldonado,R; Robledo,P] Laboratorio de Neurofarmacología, Department de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.es
dc.type.subtypeArtículoes
Appears in Collections:01- Artículos - IBIMA. Instituto de Investigación Biomédica de Málaga
01- Artículos - Hospital Regional de Málaga

Files in This Item:
File Description SizeFormat 
GonzalezAparicioR_TheSistemicAdministration.pdfArtículo publicado404,15 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons